Tebentafusp for treating advanced uveal melanoma (TA1027)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 January 2025
Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 December 2024
Teprotumumab for treating thyroid eye disease [ID6432]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 13 August 2025
Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over [ID547]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 September 2025
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 28 January 2026
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
High-dose aflibercept for treating wet age-related macular degeneration [TSID10590]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Aflibercept for untreated diabetic macular oedema [TSID10621]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [TSID10592]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pegcetacoplan for treating geographic atrophy [ID4041]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears [TSID8472]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders [ID6430]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
NVK-002 for treating myopia in people 3 to 17 years [TSID11961]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Aflibercept for untreated retinopathy in babies born preterm TS ID 11943Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC